Maker Of Zoloft, Pfizer, Seeking Lawsuit Consolidation

We just reported that another family is alleging that the maker of the popular antidepressant, Zoloft, is responsible for their child’s birth defects, and that they are among a growing number of people claiming the same thing.

Now, due to the rising number of cases, the maker of the drug, Pfizer has requested that all federal complaints be consolidated in a multidistrict litigation. Last month, the drug maker filed a motion with the U.S. Judicial Panel on Multidistrict Litigation to have Zoloft birth defect lawsuits transferred to the Southern District of New York, where Pfizer is headquartered.

According to Pfizer, there are currently 59 lawsuits involving Zoloft, a selective serotonin reuptake inhibitor (SSRI) antidepressant, which involve common claims and questions of fact. All of the cases subject to Pfizer’s motion allege that children were born with birth defects due their mothers’ use of Zoloft during pregnancy. Zoloft birth defect lawsuits are currently pending against Pfizer in Pennsylvania, New York, Illinois, Mississippi, Missouri and Ohio.

Pfizer contends that the Southern District of New York would be suitable for the Zoloft birth defect litigation because New York has three international airports in its vicinity, making it a convenient venue for plaintiffs throughout the country. Pfizer also suggested that, as an alternative, the Northern District of Mississippi, the Southern District of Mississippi, or the Northern District of Ohio could also be suitable for the proposed Zoloft birth defect MDL.

An MDL allows lawsuits associated with a particular product to be coordinated under one judge for pretrial litigation to avoid duplicative discovery, inconsistent rulings and to conserve the resources of the parties, witnesses and the court. When lawsuits are consolidated as a multidistrict litigation, each retains its own identity. If the multidistrict litigation process does not resolve the cases, they are transferred back to the court where they originated for trial.

A growing body of research has tied Zoloft and other SSRI antidepressants to an increased risk of birth defects when they are used in pregnancy, especially the earliest stages when many women are unaware that they are pregnant.

In July 2006, the U.S. Food & Drug Administration (FDA) warned that women who use the antidepressant Zoloft after the 20th week of pregnancy are six times more likely to give birth to a child with persistent pulmonary hypertension of the newborn (PPHN). The FDA issued this warning about Zoloft based on the results of a study in the New England Journal of Medicine that examined the risk of birth defects with Zoloft and similar antidepressants.

Since then, more evidence has accumulated linking Zoloft to birth defects.  As we’ve reported, a study published last month by researchers in Sweden linking SSRI antidepressants to lung condition called, PPHN, and another published over the summer that linked Zoloft and other SSRIs to an increased risk of autism.

It goes without saying now that Zoloft has become a very dangerous drug to take while pregnant.



, ,

No comments yet.

Leave a Reply

GET HELP NOW!
  • This field is for validation purposes and should be left unchanged.
Latest Drug Injury News

Paxil Possibly Linked To Breast Cancer Risk

Cancer researchers from the City of Hope National Medical Center announced a possible link between Paxil and breast cancer. Research focused on Paxil’s estrogen effect Researchers found that Paxil has a weak estrogen effect that could increase women’s breast cancer risks. According to lead author and chairman of City of Hope’s Department of Cancer and […]

Big Pharma under Fire for Kickbacks to Docs

Trust and honesty are the cornerstones to a doctor-patient relationship. With so many doctors receiving financial incentives to use certain medications or medical devices, patients need to know if money drives the decision making process. Doctors are required to disclose potential financial conflicts to each other at conferences, but there currently is no law forcing […]

Dietary Supplements Damage Liver

A recent study revealed a significant increase in liver damage related to dietary supplements. The study, conducted by a national network of liver specialists, found a 13% increase in serious liver damage over a 10 year span. Some of these patients required liver transplants and some have even died due to liver failure. Authors of […]

FDA Advisory Committee Supports Approval of Gilead’s HIV Reducing Drug

The pharmaceutical industry may be on the verge of one of the greatest breakthrough’s that this generation has ever seen.

U.S. Health Regulators Issue New Restrictions For Gilenya, Novartis AG’s’ Multiple Sclerosis Pill

In December 2011, the FDA issued a Drug Safety Communication concerning a patient with multiple sclerosis (MS) who died within 24 hours of taking the first dose of Gilenya (fingolimod).

Latest Medical Device Injury News

Report Raises Concerns Over Heart Defibrillator Leads

The Food and Drug Administration (FDA) has just announced that they received a report that a St. Jude Durata cardiac defibrillator lead conductor became externalized; meaning the wire carrying electricity from the heart defibrillator to the heart was exposed through its insulation, a potentially dangerous and life-threatening defect.

HeartSine Class 1 Defibrillator Recall

HeartSine sent out a letter to customers in September, warning that the defibrillators may intermittently turn on and off, eventually depleting the battery.

FDA Medical Device Approval Based On Little Evidence

More than half of the high-risk cardiovascular devices approved in the past decade had no supporting active control data.

St. Jude Medical Gets FDA Warning

St. Jude Medical Inc. said it received a FDA warning about manufacturing and quality-control problems at its Sylmar, California, plant.

Hospira Still Facing Manufacturing And Regulatory Issues

Hospira has sent out 11 device notifications so far in 2013, including recall and device corrections. The company also said it sent notices to customers about some of its infusion pumps that had to either be recalled, fixed or adjusted.